(2021 list available later in the year)
Alice Wei, USA
Memorial Sloan Kettering Cancer Center
Dr. Wei is a surgeon at Memorial Sloan Kettering Cancer Center specializing in diseases of the liver, bile duct, gallbladder and pancreas specializing in minimally invasive methods. She received her MD from McGill University, General Surgery fellowship from the University of Toronto, and HPB fellowship from the Toronto General Hospital. In addition, she holds MSc degrees in both Cell Biology and Clinical Epidemiology from the University of Toronto.
David Tuveson, USA
Cold Spring Harbor Laboratory Cancer Center
David Tuveson completed chemistry at M.I.T., an MD-PhD at Johns Hopkins, medical residency at Brigham and Women’s Hospital and a medical oncology fellowship at Dana-Farber/Harvard. While training, Dr. Tuveson co-developed KIT inhibitors with George Demetri for gastrointestinal stromal tumors, and Kras-dependent mouse cancer models with Tyler Jacks. At the University of Pennsylvania his lab generated the first mouse models of ductal pancreatic cancer, and at the University of Cambridge they identified new therapies. At Cold Spring Harbor Laboratory they developed organoid models of pancreatic cancer with Hans Clevers, enabling basic discoveries and clinical findings including signatures of “common responders” to chemotherapy. Dr. Tuveson is the Chief Scientist of the Lustgarten Foundation for pancreatic cancer research, Cancer Center Director and Roy J. Zuckerberg Professor at CSHL, and serves on the BSA of the NCI, the SAC of SU2C and the BoD of AACR. Awards include the Rita Allen, Waldenstrom and Hamdan.
Eric Schadde, USA
Rush University Medical Center Chicago
Erik Schadde divides his time between being Associate Professor of Surgery in Transplantation and Surgical Oncology at Rush University in Chicago and a Consultant in liver surgery at Cantonal Hospital Winterthur in Zurich, Switzerland. His laboratory at the Institute of Physiology at the University of Zurich and in Chicago has two post-docs working on mechanisms of rapid liver regeneration in large and small animal models. Erik trained at Tufts University in Boston, did a transplant fellowship at University of Wisconsin-Madison and he worked as a transplant surgeon in Kansas City, Saint Louis University and in Zürich. His research interest is regenerative liver surgery for complex and laparoscopic liver resections for metastatic liver disease.
Go Wakabayashi, Japan
Ageo Central General Hospital
Go Wakabayashi, earned his degrees from Keio University School of Medicine, Tokyo Japan. He trained at Department of Surgery at Massachusetts General Hospital and Harvard Medical School. After working as an Assistant Professor at Department of Surgery, Keio University School of Medicine, he got appointed as Professor and Chairman of Department of Surgery at Iwate Medical University School of Medicine in 2005. From April 2015, he moved back to Tokyo and became Director of Center for Advanced Treatment of HPB Disease, Chief of Surgical Services, and Deputy Director at Ageo Central General Hospital, which is a flagship hospital among 6,000 beds hospital complex near Tokyo. His expertise includes Hepato-Pancreatic Biliary Surgery, liver transplantation, and laparoscopic surgery. He has operated more than 150 cases of living liver transplantation and over 3000 cases of HPB surgery and laparoscopic surgery. His publications are over 300 peer review articles and book chapters related to HPB surgery, liver transplantation, and laparoscopic surgery. He was awarded Gold Medal of Video Olympics at The World Congress of Endoscopic Surgery 1996. He also practices conventional HPB surgery and aggressive surgery as well. He is the President of International Laparoscopic Liver Society and holds numerous important positions in Japanese and international surgical societies.
Greg Stavrou, Germany
Full Faculty Member Semmelweis Medical Faculty, Asklepios Campus Hamburg 04/2017
Section Chief, Hepatobiliary Surgery and Pancreatic Surgery Service since 01/2016
Department of General and Abdominal Surgery, Surgical Oncology, Asklepios Hospital Hamburg-Barmbek
(Prof. Dr.med K.J. Oldhafer)
Director, Department of General, Visceral, Thoracic and Pediatric Surgery,
Klinikum Saarbrücken (Saarbruecken General Hospital) – 10/2017
modern imaging, 3D visualization and navigation in Liver Surgery, CE-IOUS for Liver Metastases,
Hypertrophy Concepts in Liver Surgery
Joris Erdmann, Netherlands
Amsterdam University Medical Centre
Joris Erdmann is a HPB surgeon at the Amsterdam UMC. He received his MD and PhD and surgical training at the Erasmus MC Rotterdam. He followed the HPB and liver transplantation fellowship at the University Medical Center in Groningen after which he worked as a consultant transplant and HPB surgeon in Groningen and Leiden. As a former (liver) transplant surgeon he was involved in machine perfusion and regeneration. At the Amsterdam UMC his research focus is on primary liver and bile duct cancers, post-operative liver function, failure and regeneration.
Karen Nugent, UK
University of Southhampton
Karen is a Consultant General Surgeon with an interest in colorectal surgery. She is a Senior Lecturer at the University of Southampton having started there in this role in 1999. She trained at St. Catharine’s College, Cambridge before finishing her clinicals at St. Bartholomew’s Hospital in 1987. After obtaining her FRCS in 1991 she went to St. Mark’s Hospital to undertake research and a Masters in Surgery in Familial Adenomatous Polyposis. Her higher surgical training was completed in the Wessex region (Basingstoke and Southampton) as well as a 6 month period at Hopital St. Antoine, Paris. As a consultant her main clinical interests are in Anal neoplasia and Pelvic floor surgery; having set up a regional pelvic floor service and multidisciplinary team with full diagnostic facilities. As an educator she has undertaken a Masters in Education and was Head of School of Surgery for Wessex for 5 years before taking up a role as the Head of Clinical Academic Training. She has a joint academic and clinical role in Southampton. Her previous National roles include President of the Association of Coloproctology of Great Britain and Ireland, President of the Pelvic Obstetric Gynaecology Physiotherapists and President of the Coloproctology section of the Royal Society of Medicine. She sits on the NICE Interventional Advisory Committee. On a personal note, she is married to a consultant anaesthetist and has 4 children.
Marc Bemelmans, Netherlands
Marc Bemelmans completed Medical School at the Maastricht University after which he did a research fellowship on Transplant Surgery at the University of Madison, Wisconsin under supervision of Prof J Southard and Prof FO Belzer. After his surgical education in the Netherlands in 1999 he did a fellowship on HPB surgery from end 1999 till begin 2001 at the University of Paris, Paul Brousse Hospital under the supervison of Prof H Bismuth where he was further educated in liver surgery and transplant surgery. He performed several management tasks such as board member of the Dutch Society of research coming from surgical residents in the Netherlands, treasurer and board member of the Dutch Society of GI surgery, Treasurer and board member of the Dutch society of Surgery and is momentarily a Compagnon Hepatobiliare appointed by Prof H Bismuth. He is now a HPB and sarcoma surgeon in the University hospital of Maastricht and the Uniklink Aachen en is also Chairman of the board of sarcoma surgery in the south east of the Netherlands (ONCOZON). His research interest includes liver regeneration, Klatskin tumors, robotic liversurgery and complex sarcoma surgery; His research includes liver regeneration, predicting biology of cancer, Iknife techniques for surgery (especially in sarcoma surgery).
Matthew Weiss, USA
Matthew J. Weiss, MD, FACS is the Deputy Physician-in-Chief and Director of Surgical Oncology for the Northwell Cancer Institute and is a Professor of Surgery and Oncology in the Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY. He is a board certified surgeon who specializes in diseases of the pancreas and liver. He trained in general surgery at Johns Hopkins Hospital and was dual fellowship trained in both surgical oncology and hepatobiliary surgery at Memorial Sloan Kettering Cancer Center. He was previously the chief of hepatobiliary surgery at Johns Hopkins, where he was also the Director of the Pancreas and Liver Multidisciplinary Clinics and the Complex General Surgical Oncology Fellowship. He is considered an international leader in both liver and pancreas surgery and has authored over 200 peer reviewed publications in the field.
Nick O’Rourke, Australia
University of Queensland
Nicholas O’Rourke is Head of HPB surgery and Chairman of General Surgery at the Royal Brisbane Hospital in Australia. He puts down most of his surgical success to excellent training in Basingstoke Hospital under the tutelage of Myrrddin Rees. He has a long interest in laparoscopic approaches to HPB problems. He is a former President of the ANZHPBA. He’s currently involved in organisation of the IHPBA 2020 Meeting in September in Melbourne, Australia. He enjoys reading, swimming and laparoscopic surgery in far flung places.
Nicolas Demartines, Switzerland
University Hospital of Lausanne (CHUV)
Prof Demartines is Professor of Surgery, and Chairman of the Department for Visceral Surgery at the University Hospital CHUV in Lausanne Switzerland since 2006. His clinical and surgical activity focused on oncologic surgery, mainly hepato-pancreatico-biliary, colorectal surgery, and oesophagus surgery. His research interest includes the entire perioperative management and minimal invasive approaches especially in oncologic patients. In this field, nutrition and Enhanced Recovery After Surgery programs (ERAS) are now well established, and his department belongs to the international leader in this promising field. Prof Demartines is member of the ERAS Society Executive Board.
Per Sandstrøm, Sweden
He is Professor of surgery at the university hospital of Linkoping Sweden. He did his medical school education at the University of Uppsala, Sweden and after that his surgical training at the University of Linkoping. He did part of his thesis of acute pancreatitis at Flinders medical centre, Adelaide, Australia under Prof. Jim Toouli. He is now working with a focus on HPB cancer surgery and sarcomas. He is also a board member and responsible for research in the Swedish liver and bile duct cancer registry. His research focus is on liver surgical techniques and colorectal liver metastases, gallbladder cancer and hepatocellular carcinoma.
Peter Allen, USA
Duke University School of Medicine
Dr. Peter J. Allen is Professor of Surgery and Chief of the Division of Surgical Oncology Division at Duke University. He also serves as the Chief of Surgery at the Duke Cancer Institute. He is originally from the state of Maine, received his undergraduate degree from Harvard University, and his medical degree from Dartmouth. Dr Allen performed his general surgical residency at Walter Reed Army Medical Center in Washington D.C., and performed both research and clinical fellowships at Memorial Sloan Kettering. Following his training, he returned to Walter Reed where he practiced general surgical oncology. During his time as a surgical attending at Walter Reed, Dr. Allen was deployed to Iraq where he spent one year as a surgeon on a forward surgical team and was awarded the combat medical badge. Dr. Allen was recruited to Memorial Sloan-Kettering Cancer Center in 2003, and for 13 years he led the surgical efforts in the treatment of neoplastic diseases of the pancreas. During his time at Sloan Kettering, Dr. Allen held the Murray F Brennan Chair in Surgery and served as the Vice Chair for Surgical Services and the Associate Director for Clinical programs in the Rubenstein Center for Pancreatic Research. Dr. Allen joined the Duke team in 2018 as the chief of the Division of Surgical Oncology, and the Chief of Surgery in the Duke Cancer Institute. His clinical and research efforts have been focused on the development of novel diagnostic and therapeutic approaches to invasive and pre-invasive lesions of the pancreas, with a particular focus on intraductal papillary mucinous neoplasms. His research has been funded by numerous organizations and he has maintained NIH funding since 2009.
Peter Naredi, Sweden
University of Gothenburg
Peter Naredi is Professor of Surgery and Head of the Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg. After medical school at the University of Lund he trained as Resident in surgery. After defending his thesis on Tumour blood flow at the University of Gothenburg he did his postdoc at the Cancer Center, University of California, San Diego, USA. In 1997 he moved to the University of Umeå and was appointed professor of surgery and chairman of the academic unit of surgery in 2003. He has specialized in cancer surgery, especially hepatopancreaticobiliary surgery and melanoma. In 2012 he moved back to the University of Gothenburg and the Sahlgrenska university hospital. His main research areas are in clinical and basic research of cancers in the liver and pancreas. He has over 130 publications in highly ranked journals as the Cell, Lancet Oncol, JCO, PNAS, Nature Med, Nature Rev Clin Oncol, Cancer Res and Clin Ca Res.Peter Naredi is Past-president of the European Cancer Organisation (ECCO), the European Society of Surgical Oncology (ESSO), the Swedish surgical society and the Scandinavian surgical society.
Philip de Reuver, the Netherlands
Radboud Institute for Health Sciences
Philip is HPB and gastrointestinal surgeon at the Radboudumc, Nijmegen, the Netherlands. He was trained at the Academic Medical Center, University of Amsterdam. He was the 2014 fellow at the Royal North Shore Hospital, Sydney, specialized in HPB surgery. In 2013 he initiated the multicenter randomized Secure trial to investigate the effectiveness of cholecystectomy in patients with symptomatic gallstones. He currently coordinates the work of several clinical PhD students who perform clinical studies in the fields of gallstones, gallbladder cancer, shared decision making, surgical practice variation and health care efficiency. His research into gallbladder cancer encompasses aspects of both clinical and molecular research; it focusses on both molecular mechanisms behind the development of this rare type as well as the optimization of patient selection for surgery and the value of (neo) adjuvant systemic therapy in an attempt to translate results from basic science into clinical practice.
Quintus Molenaar, the Netherlands
University Medical Center Utrecht
Quintus Molenaar is a professor of Hepato-Pancreato-Biliary Surgery at the Regional Academic Cancer Center Utrecht and the University Medical Center Utrecht, the Netherlands and is leading the HPB program performing approximately 200 HPB operations per year. He is Co-founder and Board Member of the Dutch Pancreatic Cancer Group, Co-founder and former Board Member of the Dutch Pancreatic Biobank, Board Member of the Dutch Hepato-Pancreato-Biliary Association and Member of the Research Commission of the Dutch Steering Group Liver Surgery. He is a proctor for robotic HPB surgery. He is Principal Investigator of several national and international studies on the treatment of patients with resectable, locally advanced and recurrent pancreatic cancer. In 2016 he performed the first Robotic assisted Whipple in the Netherlands. The Regional Academic Cancer Center Utrecht (RAKU) has fully integrated robotic HPB surgery into her practice performing over 250 HPB operations per year of which approximately 30% robot- assisted.
Rob Padbury, Australia
Southern Adelaide Local Health Network, SA Health
Director of Surgery and Perioperative Medicine in the Southern Adelaide Local Health Network, SA Health. Predominant clinical practice interest is HPB Surgery. Predominant leadership interest is clinical practice improvement, clinical standardisation and reducing variation with clinical protocols. Research interests are predominantly clinical and epidemiological, and has 111 publications. Chairman, State Surgical Taskforce from inception until April 2015. Director, SA Centre of Healthcare Improvement 2008-2013. Undertook review of Tasmanian Surgical Services 2014 and Western Australian upper GI Surgery in 2016.
Amsterdam University Medical Centers
As a Hepato-Pancreatico-Biliary (HPB) Surgeon in the Amsterdam UMC (a recent merger of the AMC and VUmc), Dr. Swijnenburg’s research focusses on multimodality molecular imaging to allow integration of diagnostic and intraoperative imaging in patients suffering from tumors in the liver, pancreas and biliary tract.
After obtaining his medical degree in 2006, he spent three years at Stanford University studying molecular imaging of embryonic stem cell transplantation, for which he received a PhD degree at the Leiden University (Prof. dr. J.F. Hamming, Prof. Dr. R.C. Robbins and Dr. J.C. Wu). This research was supported by grants from the European Society for Organ Transplantation and the Fulbright Foundation. Upon returning to The Netherlands, he started Surgery Residency at the Leiden University Medical Center and the Bronovo Hospital in The Hague. He became interested in surgical oncology, specifically hepatobiliary and pancreatic cancers and got the opportunity to join the Image-Guided Surgery research group (Prof. Dr. C. van de Velde, Dr. A.L. Vahrmeijer) at the LUMC. In 2011, he worked full time for a year as a post-doc. In 2010, he co-founded the Lisa Waller Hayes Foundation (www.lwhfoundation.com). This foundation is dedicated to advance scientific research in the field of pancreatic cancer and to provide a platform of information to patients and their families. After finishing training as a surgical oncologist in July 2015, he did a 2-year fellowship in HPB surgery at the LUMC. During that time, he instigated renewed collaboration with Stanford University’s Multimodality Molecular Imaging Lab (Prof. Dr. S.S. Gambhir) and gathered funding from several sources to allow PhD and graduate students to spent 1-2 years at Stanford. Joint projects primarily focus on the development and clinical translation of molecularly-targeted, tumor-specific imaging agents. In August of 2018, he was appointed staff member in HPB surgery at Amsterdam UMC. In that same year, he was awarded a Young Investigator Grant by the Dutch Cancer Foundation (KWF), which has allowed him to form his own research group. Currently, he is the supervisor of 5 PhD candidates and several graduate students at Amsterdam UMC and the LUMC. His clinical focus is mainly on colorectal liver metastases, cholangiocarcinoma and pancreatic cancer.
T. Peter Kingham, USA
Memorial Sloan Kettering Cancer Center
Peter Kingham was appointed to the staff at Memorial Sloan Kettering Cancer Center (MSKCC) on the Hepatopancreatobiliary Surgery Service in August, 2010. Prior to my appointment I completed a two-year fellowship in surgical oncology at MSKCC. I am also co-founder of a non-profit organization called Surgeons OverSeas. Since 2001 I have been collaborating with surgical colleagues in sub-Saharan Africa working on surgical oncology and general surgical development projects. My early research demonstrated the importance of surgery as a component of public health. Now, my research is focused on defining disparities in cancer care, cancer outcomes, surgical oncology training, and introducing new diagnostic tests in low- and middle-income countries. After documenting the differences in the metastatic presentation of patients with colorectal cancer in Nigeria, prospective studies exploring these differences and community based screening projects for colorectal cancer are underway. We have also formed a consortium of investigators in 5 hospitals in Nigeria centered on gastrointestinal malignancies. This project has created a robust clinical, pathologic, and radiologic database with good quality assurance. I have mentored and trained surgeons from Nigeria, Sierra Leone, Ghana, Kenya, Rwanda, and Malawi. As the Director of Global Cancer Disparity Initiatives at MSKCC I am now expanding our training and research efforts to additional sites in Africa.
Andrew G Renehan, UK
University of Manchester
Professor Andrew Renehan is professor of cancer studies and surgery at the University of Manchester, and researcher at the Manchester Cancer Research Centre and the NIHR Manchester Biomedical Research Centre, United Kingdom. He is honorary consultant in Colorectal and Peritoneal Surgical Oncology at the Christie NHS Foundation Trust, Manchester. He leads research in the following areas: (i) anorectal cancer functional outcomes including organ preservation approaches; (ii) obesity-links with cancer incidence and outcomes; and (iii) has had a long-term interest in follow-up after curative resection for colorectal cancer, and was on the steering committee of the COLOFOL trial. He was a member of the IARC handbook writing group on weight control and cancer; and is chair of the EASD Diabetes and Cancer Study Group. He is part of the CRUK Alliance for Cancer Early Detection. He uses a variety of advanced statistical methodologies to support his research including causal inference modelling, advanced meta-analysis methods, and quasi-experiments designs through observational data.
Sander Rensen, the Netherlands
Sander Rensen is associate professor at the Department of Surgery at Maastricht University. He was trained as a molecular biologist at Maastricht University. His main research interest is cancer cachexia. His research group aims to identify mechanisms underlying tumour-induced metabolic disturbances in cancer patients. Deep clinical phenotyping of cachexia-related parameters in patients is integrated with experimental data from tumour organoid models. In parallel, he focuses on improving organoid culture techniques to facilitate their application in personalized medicine through therapeutic cancer vaccines and drug screening approaches.